PT  - JOURNAL ARTICLE
AU  - Sahashi, Yuki
AU  - Vukadinovic, Milos
AU  - Amrollahi, Fatemeh
AU  - Trivedi, Hirsh
AU  - Rhee, Justin
AU  - Chen, Jonathan
AU  - Cheng, Susan
AU  - Ouyang, David
AU  - Kwan, Alan C.
TI  - Opportunistic Screening of Chronic Liver Disease with Deep Learning Enhanced Echocardiography
AID  - 10.1101/2024.06.13.24308898
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.13.24308898
4099  - http://medrxiv.org/content/early/2024/06/14/2024.06.13.24308898.short
4100  - http://medrxiv.org/content/early/2024/06/14/2024.06.13.24308898.full
AB  - Importance Chronic liver disease affects more than 1.5 billion adults worldwide, however the majority of cases are asymptomatic and undiagnosed. Echocardiography is broadly performed and visualizes the liver; but this information is not leveraged.Objective To develop and evaluate a deep learning algorithm on echocardiography videos to enable opportunistic screening for chronic liver disease.Design Retrospective observational cohortsSetting Two large urban academic medical centersParticipants Adult patients who received echocardiography and abdominal imaging (either abdominal ultrasound or abdominal magnetic resonance imaging) with ≤30 days between tests, between July 4, 2012, to June 4, 2022.Exposure Deep learning model predictions from a deep-learning computer vision pipeline that identifies subcostal view echocardiogram videos and detects the presence of cirrhosis or steatotic liver disease (SLD).Main Outcome and Measures Clinical diagnosis by paired abdominal ultrasound or magnetic resonance imaging (MRI).Results A total of 1,596,640 echocardiogram videos (66,922 studies from 24,276 patients) from Cedars-Sinai Medical Center (CSMC) were used to develop EchoNet-Liver, an automated pipeline that identifies high quality subcostal images from echocardiogram studies and detects the presence of cirrhosis or SLD. In the held-out CSMC test cohort, EchoNet-Liver was able to detect the presence of cirrhosis with an AUC of 0.837 (0.789 - 0.880) and SLD with an AUC of 0.799 (0.758 - 0.837). In a separate test cohort with paired abdominal MRIs, cirrhosis was detected with an AUC of 0.704 (0.689-0.718) and SLD was detected with an AUC of 0.726 (0.659-0.790). In an external test cohort of 106 patients (n = 5,280 videos), the model detected cirrhosis with an AUC of 0.830 (0.738 - 0.909) and SLD with an AUC of 0.768 (0.652 – 0.875).Conclusions and Relevance Deep learning assessment of clinical echocardiography enables opportunistic screening of SLD and cirrhosis. Application of this algorithm may identify patients who may benefit from further diagnostic testing and treatment for chronic liver disease.Question Can a deep learning algorithm applied to echocardiography videos effectively identify chronic liver diseases including cirrhosis and steatotic liver disease (SLD)?Findings This retrospective observational cohort study utilized 1,596,640 echocardiography videos from 66,922 studies of 24,276 patients. The deep learning model with a computer vision pipeline (EchoNet-Liver) demonstrated strong performance to detect cirrhosis and SLD. External validation at a geographically distinct site demonstrated similar discriminative ability.Meaning The application of EchoNet-Liver to echocardiography could aid opportunistic screening of chronic liver diseases, providing a unique cost-effective angle to improve patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYS reports support from the KAKENHI (Japan Society for the Promotion of Science: 24K10526), oversea research grant from SUNRISElab, Japan Heart Foundation and Ogawa Foundation and honoraria for lectures from m3.com inc. DO reports support from the National Institute of Health (NIH; NHLBI R00HL157421 and R01HL173526) and Alexion, and consulting or honoraria for lectures from EchoIQ, Ultromics, Pfizer, InVision, the Korean Society of Echocardiography, and the Japanese Society of Echocardiography. ACK reports consulting fees from InVision and support from the American Heart Association (AHA; 23CDA1053659) and National Institutes of Health (NIH; UL1TR001881).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Stanford University and Cedars Sinai Medical Center gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCode is available at https://github.com/echonet/liver/ and training data is available with submission of a research protocol and approval by CSMC and SHC IRBs.AIArtificial intelligenceAUROCArea under receiver operating characteristicAUPRCArea Under precision recall curveCLDchronic liver diseaseCVDcardiovascular diseaseLVEFLeft ventricular ejection fractionPRPrecision-recallSLDsteatotic liver diseasePPVpositive predictive valueNPVnegative predictive valueMRImagnetic resonance imagingMRSmagnetic resonance spectroscopyPDFFproton density fat fraction